New Findings Demonstrate Potential Benefits Of GATTEX? (teduglutide) In Phase 3 Study Of Patients With Short Bowel Syndrome

Clinical investigators presented new data from three sub-studies in patients with short bowel syndrome (SBS) who received GATTEX? (teduglutide) during a 24-week, placebo-controlled Phase 3 clinical trial. Results were presented at the annual Digestive Disease Week (DDW) Congress taking place in Chicago.

More: continued here

Filed under: Clinical Trials on June 5th, 2009